Molecular alterations in triple-negative breast cancer-the road to new treatment strategies.

By Carsten Denkert, C. Liedtke, Andrew Tutt, G. von Minckwitz. The Lancet, 2017

699 citations recorded by the source corpus.

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

Breast cancer development and progression: Risk factors, cancer stem cells, signaling pathways, genomics, and molecular pathogenesis (2018, methodology): “The diagnosis of TNBC relies on the accurate determination of ER and PR protein levels by immunohistochemistry (IHC) and of HER2 by IHC and/or fluorescence in situ hybridization (FISH).(286,287) Such accurate assessment is crucial to avoid false diagnosis of ERnegative and/or HER2-negative disease i”
Recent advances in therapeutic strategies for triple-negative breast cancer (2022, background): “It is worth mentioning that a deficiency in homologous recombination, which is partly associated with the loss of breast cancer susceptibility gene (BRCA) function in BC, is correlated with a good response to cisplatin treatment [11].”
A Structured Tumor-Immune Microenvironment in Triple Negative Breast Cancer Revealed by Multiplexed Ion Beam Imaging (2018, neutral): “Experimental model and subject details Samples of TNBC patients of no special type (ER and PR positivity less than 1%, HER2 unamplified and Her2 not 3), as well as tonsil, lymph node, placenta, gastrointestinal tract and breast carcinoma controls were obtained from Stanford Pathology department.”